• Neos Therapeutics

  Participated · Equity · Feb 2015

  Neos Therapeutics develops extended‑release and controlled‑release oral formulations for Attention‑Deficit Hyperactivity Disorder (ADHD), including oral disintegrating tablets (ODT) and liquid suspensions. The company has three proprietary products in late‑stage development and a late‑stage pipeline focused on patient‑friendly dosage forms. It also manufactures and markets a generic of Tussionex® extended‑release oral suspension for cough and upper respiratory symptoms. Led by President and CEO Vipin K. Garg, Ph.D., Neos is pursuing regulatory approvals for its candidates. The company completed a $20.6M funding round to support ongoing development. Planned uses of proceeds include the FDA review of NT‑0102 and submission of NDAs for an amphetamine XR‑ODT and an amphetamine XR‑Liquid Suspension. Neos Therapeutics is a Grand Prairie, TX‑based oral drug delivery company focused on controlled‑release (CR) products for ADHD. The company develops and manufactures FDA‑approved drug products leveraging proprietary delivery technologies, including Dynamic Time Release Suspension® (DTRS®) and Rapidly Disintegrating Ionic Masking™ (RDIM™). Its technologies enable delivery of CR small‑molecule APIs in liquid and orally disintegrating tablet (ODT) dosage forms. Neos advances targeted proprietary Rx products by utilizing APIs that are already FDA‑approved to reduce development and regulatory risk and pursue the NDA approval pathway. Led by CEO Vipin K. Garg, Ph.D., the company recently raised financing and plans to use proceeds to obtain FDA approval for three ADHD products, expand its CR ODT and CR liquid programs, and refinance existing debt. Neos Therapeutics develops and manufactures FDA‑targeted drug products that use proprietary delivery technologies (DTRS® and RDIM™) to provide controlled‑release small‑molecule APIs in liquid and orally disintegrating tablet forms. The company pursues products built on APIs that are already FDA‑approved to reduce development and regulatory risk and accelerate NDAs. Its late‑stage pipeline includes three ADHD products being developed with its controlled‑release technologies. Neos recently commercialized a generic extended‑release cough/cold product (a generic of Tussionex®) that it developed and manufactures. The company completed an oversubscribed additional Series C financing to strengthen its financial position. Proceeds are intended to support FDA approvals of the existing pipeline and to expand the use of its CR technologies to additional ODT and liquid products.

No current team members are available.